Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for ...
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain THE WOODLANDS, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, …